James Altucher

A Seeking Alpha post by noted writer, entrepreneur, and investor James Altucher has sent shares of small-cap company Neonode (NASDAQ: NEON) up 27% to $6.08 on Wednesday. Altucher argues that the stock could be worth north of $30.00 per share. The basis for his argument is twofold. First, according...

Writer, investor, trader, and entrepreneur James Altucher has a large following of market participants as well as just general fans of his work. In fact, @jaltucher has nearly 43,000 Twitter followers. He is a pretty popular guy now days and Benzinga is also an admirer of his work and pays...

These 10 tips could prevent your startup from facing certain doom. "You can go it alone for a while, but eventually team is everything," advises Scott Bell, CEO of the wealth management firm MyGDP. Second, Bell told Benzinga that you should "read James Altucher's How to Have a BIG Idea. And then...

Vringo is currently trading down over 20% on the current session. The stock had seen a tremendous rally over the last two sessions after famed blogger and entrepreneur James Altucher posted on Tech Crunch arguing that the company was likely to receive a massive cash settlement from Google (NASDAQ:...

Noted writer and investor James Altucher, posted an interesting piece at techcrunch.com this weekend which has caused a huge spike in shares of Vringo, Inc. (NASDAQ: VRNG). The entire story is fairly in-depth, but essentially, Altucher argues that VRNG could potentially see a big payday relating to...

Are you attending this year's International Traders Expo? If not, here are five reasons that could change your mind. With more than 100 speakers and over 200 free workshops and special events, the International Traders Expo is the leading New York event for traders to gather, learn and discuss...

If Star Scientific's (NASDAQ: CIGX) press release is to be believed, we might be on the precipice of a genuine breakthrough. James Altucher took a moment to translate the confusing and unusually written press release into what he calls “Investor-English.” His conclusion is that Star Scientific has...

James Altucher has an excellent post on his site about 10 things he's learned by working with Jim Cramer. Altucher first met Cramer when "Mad Money" was first starting on CNBC, despite having worked for TheStreet.com (NASDAQ: TSCM) for years writing articles, and creating and ultimately selling...

Rodman & Renshaw has downgraded shares of PharmAthene, Inc. (NYSE: PIP) to Underperform from Market Perform, and has set a price target at $2.50. Rodman said that it believes the best-case scenario outcome of an ongoing lawsuit is already priced into the stock, adding that PharmAthene is more...

James Altucher has written an article on Giant Interactive (NYSE: GA), and has called it the cheapest stock in China, based off financial metrics. Altucher is long GA and gives reasons why he thinks it's a double from here, and why he is long the stock. Altucher notes that the company has $860...